

We claim:

sub 8/10
1. A method for inhibiting microvascular bleeding in a patient comprising administering to the patient an effective amount to block greater than 90% of activated protein C in human plasma of an inhibitor of a natural anticoagulant selected from the group consisting of protein C, antithrombin III, heparin cofactor II, thrombomodulin and tissue factor inhibitor pathway in a pharmaceutically acceptable carrier.

2. The method of claim 1 wherein the natural anticoagulant is protein C.

sub 8/10
3. The method of claim 1 wherein the inhibitor is administered systemically.

4. The method of claim 1 wherein the inhibitor is administered topically.

sub 8/10
5. The method of claim 1 further comprising administering at the site of the bleeding a coagulant.

6. The method of claim 5 wherein the coagulant is selected from the group consisting of thrombin and tissue thromboplastin.

sub 8/10
7. The method of claim 3 wherein the inhibitor is an antibody to protein C.

sub 8/10
8. The method of claim 7 wherein the inhibitor is administered systemically in combination with topical administration of a coagulant at the site of bleeding.

9. The method of claim 8 wherein the topically administered coagulant is selected from the group consisting of thrombin in a dosage of between approximately 1000 and 10,000 units and tissue factor in a dosage of between approximately 0.1 and 10 mg.

sub 8/10
10. The method of claim 1 wherein the inhibitor is administered to a patient to stop microvascular bleeding.

sub 8/10
11. The method of claim 10 wherein the inhibitor is administered to a burn patient.

12. The method of claim 10 wherein the inhibitor is administered to a patient with tissue or skin grafts.

13. The method of claim 10 wherein the inhibitor is administered to a patient with cerebral contusions.

14. A composition for inhibition of microvascular bleeding comprising an inhibitor of a natural anticoagulant selected from the group consisting of protein C, thrombomodulin, antithrombin III, heparin cofactor II and tissue factor inhibitor pathway in combination with a coagulant in a pharmaceutically acceptable carrier.

15. The composition of claim 14 wherein the inhibitor specifically inhibits protein C.

16. The composition of claim 14 wherein the coagulant is selected from the group consisting of thrombin and tissue thromboplastin.

17. The composition of claim 14 wherein the coagulant is selected from the group consisting of thrombin and tissue thromboplastin.

Board
decision

add

add